Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
NASDAQ:EDIT
Price:
5.22 USD
-2.43%
Market Closed
Updated:
Apr 26, 2024
Editas Medicine Inc
Cash from Operating Activities
|
Editas Medicine Inc
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Cash from Operating Activities
-$132.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Editas Medicine Inc's Cash from Operating Activities?
Cash from Operating Activities
-132.2m
USD
-132.2m
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Cash from Operating Activities amounts to -132.2m USD.
What is Editas Medicine Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-24%
-24%
Over the last year, the Cash from Operating Activities growth was 25%. The average annual Cash from Operating Activities growth rates for Editas Medicine Inc have been 10% over the past three years , -24% over the past five years .
You don't have any saved screeners yet
